275 related articles for article (PubMed ID: 23485065)
1. Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor.
Weiss DR; Ahn S; Sassano MF; Kleist A; Zhu X; Strachan R; Roth BL; Lefkowitz RJ; Shoichet BK
ACS Chem Biol; 2013 May; 8(5):1018-26. PubMed ID: 23485065
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study.
Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
J Chem Inf Model; 2015 May; 55(5):1045-61. PubMed ID: 25848966
[TBL] [Abstract][Full Text] [Related]
3. Do crystal structures obviate the need for theoretical models of GPCRs for structure-based virtual screening?
Tang H; Wang XS; Hsieh JH; Tropsha A
Proteins; 2012 Jun; 80(6):1503-21. PubMed ID: 22275072
[TBL] [Abstract][Full Text] [Related]
4. Structural features of β2 adrenergic receptor: crystal structures and beyond.
Bang I; Choi HJ
Mol Cells; 2015; 38(2):105-11. PubMed ID: 25537861
[TBL] [Abstract][Full Text] [Related]
5. Comparative Docking to Distinct G Protein-Coupled Receptor Conformations Exclusively Yields Ligands with Agonist Efficacy.
Scharf MM; Bünemann M; Baker JG; Kolb P
Mol Pharmacol; 2019 Dec; 96(6):851-861. PubMed ID: 31624135
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the β2-adrenergic receptor.
Goetz A; Lanig H; Gmeiner P; Clark T
J Mol Biol; 2011 Dec; 414(4):611-23. PubMed ID: 22037586
[TBL] [Abstract][Full Text] [Related]
7. Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody.
Ring AM; Manglik A; Kruse AC; Enos MD; Weis WI; Garcia KC; Kobilka BK
Nature; 2013 Oct; 502(7472):575-579. PubMed ID: 24056936
[TBL] [Abstract][Full Text] [Related]
8. Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models.
Vilar S; Ferino G; Phatak SS; Berk B; Cavasotto CN; Costanzi S
J Mol Graph Model; 2011 Feb; 29(5):614-23. PubMed ID: 21146435
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
Weichert D; Stanek M; Hübner H; Gmeiner P
Bioorg Med Chem; 2016 Jun; 24(12):2641-53. PubMed ID: 27132867
[TBL] [Abstract][Full Text] [Related]
10. Identifying Functional Hotspot Residues for Biased Ligand Design in G-Protein-Coupled Receptors.
Nivedha AK; Tautermann CS; Bhattacharya S; Lee S; Casarosa P; Kollak I; Kiechle T; Vaidehi N
Mol Pharmacol; 2018 Apr; 93(4):288-296. PubMed ID: 29367258
[TBL] [Abstract][Full Text] [Related]
11. Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors.
Lakkaraju SK; Yu W; Raman EP; Hershfeld AV; Fang L; Deshpande DA; MacKerell AD
J Chem Inf Model; 2015 Mar; 55(3):700-8. PubMed ID: 25692383
[TBL] [Abstract][Full Text] [Related]
12. Modeling G protein-coupled receptors in complex with biased agonists.
Costanzi S
Trends Pharmacol Sci; 2014 Jun; 35(6):277-83. PubMed ID: 24793542
[TBL] [Abstract][Full Text] [Related]
13. Studies on the interactions between β2 adrenergic receptor and Gs protein by molecular dynamics simulations.
Feng Z; Hou T; Li Y
J Chem Inf Model; 2012 Apr; 52(4):1005-14. PubMed ID: 22404225
[TBL] [Abstract][Full Text] [Related]
14. Simulations of biased agonists in the β(2) adrenergic receptor with accelerated molecular dynamics.
Tikhonova IG; Selvam B; Ivetac A; Wereszczynski J; McCammon JA
Biochemistry; 2013 Aug; 52(33):5593-603. PubMed ID: 23879802
[TBL] [Abstract][Full Text] [Related]
15. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation.
Staus DP; Strachan RT; Manglik A; Pani B; Kahsai AW; Kim TH; Wingler LM; Ahn S; Chatterjee A; Masoudi A; Kruse AC; Pardon E; Steyaert J; Weis WI; Prosser RS; Kobilka BK; Costa T; Lefkowitz RJ
Nature; 2016 Jul; 535(7612):448-52. PubMed ID: 27409812
[TBL] [Abstract][Full Text] [Related]
16. Modeling GPCR active state conformations: the β(2)-adrenergic receptor.
Simpson LM; Wall ID; Blaney FE; Reynolds CA
Proteins; 2011 May; 79(5):1441-57. PubMed ID: 21337626
[TBL] [Abstract][Full Text] [Related]
17. Ligand-binding affinity of alternative conformers of human β
Dilcan G; Doruker P; Akten ED
Chem Biol Drug Des; 2019 May; 93(5):883-899. PubMed ID: 30637937
[TBL] [Abstract][Full Text] [Related]
18. Structure-Guided Screening for Functionally Selective D
Männel B; Jaiteh M; Zeifman A; Randakova A; Möller D; Hübner H; Gmeiner P; Carlsson J
ACS Chem Biol; 2017 Oct; 12(10):2652-2661. PubMed ID: 28846380
[TBL] [Abstract][Full Text] [Related]
19. GPCR agonist binding revealed by modeling and crystallography.
Katritch V; Abagyan R
Trends Pharmacol Sci; 2011 Nov; 32(11):637-43. PubMed ID: 21903279
[TBL] [Abstract][Full Text] [Related]
20. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography.
Wacker D; Fenalti G; Brown MA; Katritch V; Abagyan R; Cherezov V; Stevens RC
J Am Chem Soc; 2010 Aug; 132(33):11443-5. PubMed ID: 20669948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
